CSIMarket
 
Evofem Biosciences Inc   (EVFM)
Other Ticker:  
 
 
Price: $0.0187 $0.00 -8.780%
Day's High: $0.02 Week Perf: -6.03 %
Day's Low: $ 0.02 30 Day Perf: -43.33 %
Volume (M): 375 52 Wk High: $ 1.94
Volume (M$): $ 7 52 Wk Avg: $0.18
Open: $0.02 52 Wk Low: $0.01



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 730
 Employees -
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) 44
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Evofem Biosciences Inc
Evofem Biosciences Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative products to address unmet needs in women's sexual and reproductive health. The company is committed to empowering women by providing them with safe and effective options for contraception and prevention of sexually transmitted infections.

Evofem's lead product candidate is Phexxi, a non-hormonal contraceptive gel that is designed to be bioadhesive and pH-regulating. Phexxi is intended to be used by women immediately before sexual intercourse to prevent pregnancy.

In addition to Phexxi, Evofem is also working on developing other novel product candidates for contraceptive and women's health indications. The company is dedicated to advancing scientific research and leveraging technology to improve the lives of women worldwide.

Evofem Biosciences Inc aims to address the gaps and limitations in current options available to women for contraception and sexual health. Through its innovative approach and commitment to women's health, the company strives to make a positive impact on women's lives and improve their overall well-being.


   Company Address: 7770 Regents Road San Diego 92122 CA
   Company Phone Number: 550-1900   Stock Exchange / Ticker: EVFM
   EVFM is expected to report next financial results on April 26, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Evofem Biosciences Inc

Evofem Biosciences Inc's Profits Plunge Dramatically in the Fiscal Third Quarter of 2023: Is the Company in Crisis?

Evofem Biosciences Inc (NASDAQ: EVFM) has seen a substantial turnaround in its financial performance in the third quarter of 2023, signaling positive growth and potential for investors. The company reported earnings per share (EPS) of $0.10, compared to a loss of $0.04 per share in the same period the previous year. Furthermore, its net profit per share turned positive, improving from a loss of $5.43 per share in the preceding reporting period.
Although there was a decline in revenue of -19.761% to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior, there was a significant sequential increase of 107.974% from $2.46 million. This shows a positive trend in the company's revenue generation capabilities.

Evofem Biosciences Inc

Evofem Biosciences Inc Faces Steep Decline with -59.264% Drop in Revenue, Investors Worried



Evofem Biosciences Inc (EVFM) has recently reported its financial results for the quarter ended June 30, 2023, and the numbers paint a bleak picture for the company. Revenue has taken a significant hit, declining by -59.264% to $2.46 million compared to the corresponding quarter a year prior. The net deficit per share has expanded to $-5.43, compared to $-1.85 per share in the previous quarter. Additionally, the company witnessed a drastic decline in revenue of -57.686%, falling from $5.81 million in the previous quarter. These abysmal figures have raised concerns among investors and market analysts.
The Q2 Numbers:
During the April to June 2023 fiscal timeframe, Evofem Biosciences Inc reported a net loss of $-8.558 million, a noteworthy improvement from the hefty deficit of $-124.072 million in the corresponding quarter the previous year. The company managed to narrow down its losses, but it was not enough to offset the declining revenue.

Evofem Biosciences Inc

Evofem Biosciences Inc Still Unprofitable Despite 36.65% Revenue Surge in Q1 2023

Evofem Biosciences Inc, a major pharmaceutical preparations company, faced losses in the first quarter of the 2023 earnings season. The company recorded a loss of $-1.85 per share during this period. However, there was a substantial increase in revenue, which saw a surge of 36.65% to $5.81 million compared to the same reporting season a year ago.
To provide some context, in the preceding reporting season, the company generated revenue of $0.18 million with a loss of $-0.10 per share. The significant growth in revenue for the first quarter of 2023 is an encouraging sign, especially when compared to the modest earning in the previous season.






 

Evofem Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com